{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:51:51Z","timestamp":1794264711523,"version":"4.9.0"},"reference-count":56,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Introduction: Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy is the standard of care for high-risk and intermediate-risk non-muscle-invasive bladder cancer (NMIBC) as well as for Carcinoma in situ (CIS). Evidence supports that the different BCG strains, despite genetic variability, are equally effective clinically for preventing the recurrence and progression of papillary NMIBC. The available evidence regarding possible differences in clinical efficacy between various BCG strains in CIS is lacking. Methods: We reviewed the literature on the efficacy of different BCG strains in patients with CIS (whether primary, secondary, concomitant, or unifocal\/multifocal), including randomized clinical trials (RCTs), phase II\/prospective trials, and retrospective studies with complete response rates (CRR), recurrence-free survival (RFS), or progression-free survival (PFS) as endpoints. Results: In most studies, being RCTs, phase II prospective trials, or retrospective studies, genetic differences between BCG strains did not translate into meaningful differences in clinical efficacy against CIS, regardless of the CIS subset (primary, secondary, or concurrent) or CIS focality (unifocal or multifocal). CRR, RFS, and PFS were not statistically different between various BCG strains. None of these trials were designed as head-to-head comparisons between BCG strains focusing specifically on CIS. Limitations include the small sample size of many studies and most comparisons between strains being indirect rather than head-to-head. Conclusions: This review suggests that the clinical efficacy of the various BCG strains appears similar, irrespective of CIS characteristics. However, based on the weak level of evidence available and underpowered studies, randomized studies in this space should be encouraged as no definitive conclusion can be drawn at this stage.<\/jats:p>","DOI":"10.3390\/cancers16020245","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T03:43:00Z","timestamp":1704426180000},"page":"245","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Carcinoma In Situ (CIS): Is There a Difference in Efficacy between Various BCG Strains? A Comprehensive Review of the Literature"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2726-4273","authenticated-orcid":false,"given":"Andres","family":"Llano","sequence":"first","affiliation":[{"name":"Division of Urology, Department of Surgical Oncology, Department of Surgery, Sinai Health System, University of Toronto, Toronto, ON M5G 2N2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Chan","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgical Oncology, Department of Surgery, Sinai Health System, University of Toronto, Toronto, ON M5G 2N2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Kuk","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgical Oncology, Department of Surgery, Sinai Health System, University of Toronto, Toronto, ON M5G 2N2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"Kassouf","sequence":"additional","affiliation":[{"name":"Division of Urology, McGill University Health Center, Montreal, QU H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2315-5809","authenticated-orcid":false,"given":"Alexandre R.","family":"Zlotta","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgical Oncology, Department of Surgery, Sinai Health System, University of Toronto, Toronto, ON M5G 2N2, Canada"},{"name":"Division of Urology, Department of Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Heath Network, University of Toronto, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"key":"ref_1","first-page":"E424","article-title":"Canadian Urological Association Guideline on the Management of Non-Muscle-Invasive Bladder Cancer\u2014Full-Text","volume":"15","author":"Bhindi","year":"2021","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on Non\u2013muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.eururo.2014.10.040","article-title":"Diagnosis and management of urothelial carcinoma in situ of the Lower Urinary Tract: A Systematic Review","volume":"67","author":"Casey","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.euo.2020.12.002","article-title":"Prognostic Value of the WHO1973 and WHO2004\/2016 Classification Systems for Grade in Primary Ta\/T1 Non\u2013muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non\u2013muscle-invasive Bladder Cancer Guidelines Panel Study","volume":"4","author":"Hentschel","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non\u2013muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: An update from the EAU NMIBC guidelines panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.euf.2019.03.012","article-title":"Carcinoma in situ of the urinary bladder: A systematic review of current knowledge regarding detection, treatment, and outcomes","volume":"6","author":"Subiela","year":"2020","journal-title":"Eur. Urol. Focus"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.juro.2010.03.032","article-title":"Clinical outcomes of primary bladder carcinoma in situ in a contemporary series","volume":"184","author":"Chade","year":"2010","journal-title":"J. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.juro.2010.03.134","article-title":"Clinical outcome of primary versus secondary bladder carcinoma in situ","volume":"184","author":"Chade","year":"2010","journal-title":"J. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Russo, G.I., Sholklapper, T.N., Cocci, A., Broggi, G., Caltabiano, R., Smith, A.B., Lotan, Y., Morgia, G., Kamat, A.M., and Witjes, J.A. (2021). Performance of narrow band Imaging (NBI) and photodynamic diagnosis (PDD) fluorescence imaging compared to white light cystoscopy (WLC) in detecting non-muscle invasive bladder cancer: A systematic review and lesion-level diagnostic meta-analysis. Cancers, 13.","DOI":"10.3390\/cancers13174378"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Xiong, Y., Li, J., Ma, S., Ge, J., Zhou, L., Li, D., and Chen, Q. (2017). A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0170819"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e028173","DOI":"10.1136\/bmjopen-2018-028173","article-title":"Diagnostic performance of image technique based transurethral resection for non-muscle invasive bladder cancer: Systematic review and diagnostic meta-analysis","volume":"9","author":"Chen","year":"2019","journal-title":"BMJ Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.eururo.2013.03.059","article-title":"Photodynamic diagnosis of non\u2013muscle-invasive bladder cancer with hexami-nolevulinate cystoscopy: A meta-analysis of detection and recurrence based on Raw Data","volume":"64","author":"Burger","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_14","unstructured":"Bladder Cancer Staging: Bladder Cancer Stages (2023, January 23). The American Cancer Society. Available online: https:\/\/www.cancer.org\/cancer\/bladder-cancer\/detection-diagnosis-staging\/staging.html."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1158\/0008-5472.CAN-03-3620","article-title":"Gene expression in the urinary bladder: A common carcinoma in situ gene expression signature exists disregarding histopathological classification","volume":"64","author":"Thykjaer","year":"2004","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"EVIDoa2200092","DOI":"10.1056\/EVIDoa2200092","article-title":"A Randomized Trial of PHOTOdynamic Surgery in Non\u2013Muscle-Invasive Bladder Cancer","volume":"1","author":"Heer","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7308","DOI":"10.1016\/j.vaccine.2021.08.026","article-title":"A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment","volume":"39","author":"Lamm","year":"2021","journal-title":"Vaccine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41585-021-00481-1","article-title":"100 years of bacillus calmette\u2013Gu\u00e9rin immunotherapy: From cattle to COVID-19","volume":"18","author":"Lobo","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/mt.2016.18","article-title":"The BCG Strain Pool: Diversity Matters","volume":"24","author":"Bottai","year":"2016","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nrurol.2013.194","article-title":"BCG immunotherapy for bladder cancer\u2014The effects of substrain differences","volume":"10","author":"Gan","year":"2013","journal-title":"Nat. Rev. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Gu\u00e9rin strain differences have an impact on clinical outcome in Bladder Cancer immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/0974-7796.106873","article-title":"Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Gu\u00e9rin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison","volume":"5","author":"Inamoto","year":"2013","journal-title":"Urol. Ann."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.juro.2013.01.084","article-title":"A prospective comparative study of intravesical Bacillus Calmette-Gu\u00e9rin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer","volume":"190","author":"Sengiku","year":"2013","journal-title":"J. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1464-410X.1992.tb15486.x","article-title":"Intravesical BCG treatment for superficial bladder cancer: Long-term results using two dif-ferent strains of BCG","volume":"69","author":"Mukherjee","year":"1992","journal-title":"Br. J. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1464-410X.1994.tb07548.x","article-title":"Marker tumour response to Evans and Pasteur Bacille Calmette-Gu\u00e9rin in multiple recurrent PTA\/PT1 bladder tumours: Report from the Medical Research Council subgroup on superficial bladder cancer (Urological Cancer Working Party)","volume":"73","author":"Fellows","year":"1994","journal-title":"Br. J. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.acuroe.2018.03.004","article-title":"Safety and efficacy of various strains of Bacille Calmette\u2013Gu\u00e9rin in the treatment of bladder tumors in standard clinical practice","volume":"42","year":"2018","journal-title":"Actas Urol\u00f3gicas Espa\u00f1olas"},{"key":"ref_27","first-page":"E54","article-title":"Are there differences among Bacillus Calmette-Gu\u00e9rin (BCG) strains regarding their clinical efficacy in the treatment of non-muscle invasive bladder cancer? The jury is still out but the answer is likely no","volume":"14","author":"Tan","year":"2020","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_28","first-page":"306.e1","article-title":"Does switching the bacillus Calmette-Gu\u00e9rin strain affect clinical outcome in patients with recurrent non\u2013muscle-invasive bladder cancer after initial bacillus Calmette-Gu\u00e9rin therapy?","volume":"36","author":"Niwa","year":"2018","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/1097-0215(20000915)87:6<844::AID-IJC14>3.0.CO;2-5","article-title":"What are the immunologically active components of bacille Calmette-Gu\u00e9rin in therapy of superficial bladder cancer?","volume":"87","author":"Zlotta","year":"2000","journal-title":"Int. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"48","DOI":"10.6004\/jnccn.2009.0004","article-title":"Carcinoma in situ of the urinary bladder: Review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis","volume":"7","author":"Nese","year":"2009","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1080\/21681805.2016.1210672","article-title":"Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder","volume":"50","author":"Kaasinen","year":"2016","journal-title":"Scand. J. Urol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.juro.2015.08.075","article-title":"Randomized controlled study of the efficacy, safety and quality of life with low dose bacillus Calmette-Gu\u00e9rin instillation therapy for nonmuscle invasive bladder cancer","volume":"195","author":"Yokomizo","year":"2016","journal-title":"J. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1442-2042.2010.02584.x","article-title":"Maintenance intravesical bacillus Calmette-Gu\u00e9rin instillation for TA, T1 cancer and carcinoma in situ of the bladder: Randomized controlled trial by the BCG Tokyo Strain Study Group","volume":"17","author":"Koga","year":"2010","journal-title":"Int. J. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.ju.0000150425.09317.67","article-title":"Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: Results of a European organization for the research and treatment of cancer\u2014Genito-urinary group phase III trial (30906)","volume":"173","author":"Kurth","year":"2005","journal-title":"J. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus calmette-guerin the same efficacy against recurrences and progression of T1G3 and tis bladder tumors than the standard dose? Results of a prospective ran-domized trial","volume":"174","author":"Solsona","year":"2005","journal-title":"J. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized southwest oncology group study","volume":"163","author":"Lamm","year":"2000","journal-title":"J. Urol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000049765","article-title":"Intravesical BCG in patients with carcinoma in situ of the urinary bladder: Long\u2013term results of EORTC GU Group Phase II protocol 30861","volume":"40","author":"Jakse","year":"2001","journal-title":"Eur. Urol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0022-5347(17)49104-X","article-title":"The management of superficial bladder tumors and carcinoma in situ with in-travesical bacillus Calmette-Guerin","volume":"133","author":"Huang","year":"1985","journal-title":"J. Urol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.juro.2011.04.073","article-title":"Factors affecting response to bacillus Calmette-Gu\u00e9rin plus interferon for urothelial carcinoma in situ","volume":"186","author":"Rosevear","year":"2011","journal-title":"J. Urol."},{"key":"ref_40","first-page":"258","article-title":"The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-G\u00faerin immunotherapy","volume":"27","author":"Gofrit","year":"2009","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1442-2042.2008.02012.x","article-title":"Clinical outcomes of bacillus Calmette-Gu\u00e9rin instillation therapy for carcinoma in situ of urinary bladder","volume":"15","author":"Takenaka","year":"2008","journal-title":"Int. J. Urol."},{"key":"ref_42","first-page":"395","article-title":"Long-term outcome of a low-dose intravesical bacillus Calmette\u2013Guerin therapy for carcinoma in situ of the bladder: Results after six successive instillations of 40 mg BCG","volume":"35","author":"Mugiya","year":"2005","journal-title":"Ultrasound Med. Biol."},{"key":"ref_43","first-page":"433","article-title":"A prospective comparative study to assess the efficacy and tolerability of 2 different doses of intravesical bacillus Calmette-Guerin (BCG) in patients with non\u2013muscle-invasive bladder cancer","volume":"38","author":"Sood","year":"2020","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/j.clgc.2021.12.005","article-title":"Impact of age on outcomes of patients with pure carcinoma in situ of the bladder: Mul-ti-institutional cohort analysis","volume":"20","author":"Ferro","year":"2022","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1007\/s00432-021-03571-0","article-title":"Efficacy of three BCG strains (Connaught, Tice and RIVM) with or without sec-ondary resection (re-TUR) for intermediate\/high-risk non-muscle-invasive bladder cancers: Results from a retrospective sin-gle-institution cohort analysis","volume":"147","author":"Busetto","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"406","DOI":"10.23736\/S0393-2249.19.03254-5","article-title":"Predictive factors for progression of patients with carcinoma in situ of the bladder at long-term follow-up: Pure versus non-pure CIS","volume":"71","author":"Hurle","year":"2019","journal-title":"Minerva Urol. Nefrol."},{"key":"ref_47","first-page":"844","article-title":"Long-term outcome of intravesical bacillus Calmette-Gu\u00e9rin therapy with maintenance for urinary bladder carcinoma in situ: About 47 cases","volume":"94","author":"Sallami","year":"2016","journal-title":"Tunis. Med."},{"key":"ref_48","first-page":"484.e19","article-title":"The efficacy of BCG Tice and BCG Connaught in a cohort of 2,099 patients with T1G3 non\u2013muscle-invasive bladder cancer","volume":"34","author":"Witjes","year":"2016","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1014444601158","article-title":"Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guerin (Tokyo 172 strain) therapy: Signif-icance of concomitant carcinoma in situ","volume":"33","author":"Takashi","year":"2002","journal-title":"Int. Urol. Nephrol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clgc.2019.10.021","article-title":"Comparative effectiveness of intravesical BCG-Tice and BCG-Moreau in patients with non-muscle-invasive bladder cancer","volume":"18","author":"Soria","year":"2020","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Del Giudice, F., Flammia, R.S., Chung, B.I., Moschini, M., Pradere, B., Mari, A., Soria, F., Albisinni, S., Krajewski, W., and Szyde\u0142ko, T. (2022). Compared efficacy of adjuvant intravesical BCG-TICE vs. BCG-RIVM for high-risk non-muscle invasive bladder cancer (NMIBC): A propensity score matched analysis. Cancers, 14.","DOI":"10.3390\/cancers14040887"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/2090598X.2021.1874628","article-title":"Assessment of the oncological outcomes of three different bacillus Calmette\u2013Gu\u00e9rin strains in patients with high-grade T1 non-muscle-invasive bladder cancer","volume":"19","author":"Nowak","year":"2021","journal-title":"Arab. J. Urol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Koguchi, D., Matsumoto, K., Hirayama, T., Moroo, S., Kobayashi, M., Katsumata, H., Ikeda, M., and Iwamura, M. (2020). Impact of maintenance therapy using a half dose of the bacillus Calmette\u2013Gu\u00e9rin Tokyo strain on recurrence of intermediate and high-risk nonmuscle invasive bladder cancer: A retrospective single-center study. BMC Urol., 20.","DOI":"10.1186\/s12894-020-00766-4"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/S0022-5347(05)64994-4","article-title":"Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance","volume":"167","author":"Griffiths","year":"2002","journal-title":"J. Urol."},{"key":"ref_55","first-page":"398","article-title":"Immune mechanisms and molecular therapeutic strategies to enhance immunotherapy in non-muscle invasive bladder cancer: Invited review for special issue \u201cSeminar: Treatment Advances and Molecular Biology Insights in Urothelial Carcinoma\u201d","volume":"41","author":"Chu","year":"2023","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.euf.2018.08.015","article-title":"Background and Update for S1602 \u201cA Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-na\u00efve High-grade Non-muscle-invasive Bladder Cancer","volume":"4","author":"Svatek","year":"2018","journal-title":"Eur. Urol. Focus."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/2\/245\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:40:31Z","timestamp":1760103631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/2\/245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":56,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["cancers16020245"],"URL":"https:\/\/doi.org\/10.3390\/cancers16020245","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,5]]}}}